Mirati Therapeutics said Tuesday that U.S. regulators accepted an application for its KRAS-blocking lung cancer drug, but the review time will be longer than hoped.
The Food and Drug Administration granted a standard review to the Mirati drug called adagrasib, which sets the approval decision date on Dec. 14 — four months later than the company had requested.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
